Biosimilar vs. Generic Pharmaceuticals, an Industrial Info Market Brief
Biosimilar vs. Generic Pharmaceuticals, an Industrial Info Market Brief
When branded pharmaceuticals fall off the patent cliff (patent expires) and are available to be copied by other manufacturers, the terms used to describe these pharmaceuticals are generics and biosimilars. The question is, why are they not all called generics?
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Suffolk Construction Has Hand in $1.9 Billion Worth of Projects
- U.S. Home to Billions' Worth of 2Q ESG Project Kickoffs
- Japan Hosts $832 Million in CDMO/CMO-Related Pharma Projects
- Turner Construction Involved in More than $24 Billion Worth of U.S. Project...
- Medical Devices & Equipment Sector Brings Billions in Spending to the U.S.